Evoke pharma inc (EVOK)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Operating expenses:
Research and development

3,416

4,095

7,137

6,951

8,154

9,991

956

-

-

Research and development

-

-

-

-

-

-

-

1,165

1,844

General and administrative

3,737

3,919

4,093

3,592

3,664

3,158

1,644

836

570

Total operating expenses

7,154

8,014

11,230

10,544

11,818

13,150

2,601

2,002

2,414

Loss from operations

-7,154

-8,014

-11,230

-10,544

-11,818

-13,150

-2,601

-2,002

-2,414

Other income:
Interest income

28

15

6

-268

-303

-

-

-

-

Financing costs related to warrant liability

-

-

-

533

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

1

10

Interest expense

-

-

-

-

-

-

-

24

2

Gain from change in fair value of warrant liability

-

-433

1,005

-597

-

-

82

-7

-5

Interest income

-

-

-

-

-

-

7

-

-

Interest expense

-

-

-

-

-

-

159

-

-

Total other income

28

448

-998

-204

-303

-97

-234

-15

13

Net loss

-7,125

-7,566

-12,229

-10,748

-12,121

-13,247

-2,836

-2,017

-2,401

Net loss per share of common stock, basic

-

-

-0.82

-1.15

-

-

-

-

-

Net loss per share of common stock, diluted

-

-

-0.90

-1.15

-

-

-

-

-

Weighted-average shares used to compute basic net loss per share

-

-

14,897

9,338

-

-

-

-

-

Weighted-average shares used to compute diluted net loss per share

-

-

14,951

9,338

-

-

-

-

-

Net loss per share of common stock, basic and diluted

-0.32

-0.46

-

-

-1.87

-2.20

-1.20

-1.79

-2.18

Weighted-average shares used to compute basic and diluted net loss per share

22,296

16,602

-

-

6,485

6,032

2,368

1,124

1,102